#ES­MO16: Boehringer drug flops on OS end­point; Medi­vir re­or­ga­nizes, cuts staff

Fresh on the heels of an em­bar­rass­ing set­back with a lethal can­cer drug in-li­censed from Han­mi, Boehringer In­gel­heim re­port­ed over the week­end that nintedanib …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER